Clinical Trials
11 trialsNCT03240211 2026-04-07
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
University of Virginia
Phase 1 Active not recruiting
NCT07036133 2026-02-11
SPI-FOL-102
Acrotech Biopharma Inc.
Phase 1 Recruiting
NCT01206465 2023-12-26
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
University of Nebraska
Phase 1 Completed
NCT02594267 2021-07-27
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01789723 2020-01-23
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Acrotech Biopharma Inc.
Phase 1 Withdrawn
NCT01820091 2020-01-23
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Acrotech Biopharma Inc.
Phase 1 Withdrawn
NCT00554827 2020-01-03
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01114282 2016-07-06
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Stanford University
Phase 1 Completed
NCT01532011 2016-07-04
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00024245 2013-06-26
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed